Processa successfully identifies next generation capecitabine dosage regimens for phase 2b trial

Next generation capecitabine (ngc) d osage r egimens h ave b een i dentified i n t he o ngoing phase 1b t rial w ith p otentially b etter s afety a nd e fficacy p rofiles t han e xisting c hemotherapy
PCSA Ratings Summary
PCSA Quant Ranking